to patients," said Bjoern Rueter, U.S. Vice President, Clinical Development and Medical Affairs. "We are excited to join forces with Lung Cancer Research Foundation as we embark on a new era for cancer research and create the Team Science and Early...
epcoritamab containing regimen, especially in patients who progress quickly after initial treatment, and reinforce our joint efforts with AbbVie to develop epcoritamab as a core therapy for B-cell lymphomas, especially as we develop epcoritamab in...
Osteo Bi-Flex®, the number one pharmacist-recommended joint care supplement brand1 introduced its new Osteo Bi-Flex® Advanced Omega-3 Joint Complex supplement. This new formula helps support joint and whole body health by combining 100 mg of Joint...
Joint study by University of Shizuoka, Kobe University, and Noster Inc. uncovers a novel postbiotic pathway for obesity prevention.A new collaborative study from the University of Shizuoka, Kobe University, and Kyoto-based biotech company Noster...
vitality. "XPRIZE Healthspan is a pivotal opportunity to advance global health," said Dr. Jordan. "We are excited to join forces with Kimera Labs to accelerate the development of transformative breakthroughs in healthy aging." XPRIZE Healthspan...
now offering pharmaceutical-grade Niagen® IV and injections featuring patented nicotinamide riboside. These new providers join a growing network of almost 600 clinics nationwide offering the first-of-its-kind, pharmaceutical-grade NAD-boosting...
volume z-score and muscle fat infiltration in people with type 2 diabetes (T2D) The recent publication builds on previous joint efforts between AMRA and Lilly regarding the SURPASS-3 MRI substudy, which used AMRA’s unique, MRI-based visceral,...
models, leveraging Ohio State’s specialized neutron source optimized for BNCT research. In parallel, the teams will pursue joint development of next-generation boron drugs for BNCT and adjacent applications—unlocking new possibilities in precision...
Bazett, PhD, will be presenting a late-breaking poster on BOLD-100's potent neuroprotective properties Mark Bazett will be joined by Jim Pankovich, EVP Clinical Development, and Ashish Kumar, PhD, Sr. Scientist. Building on Bold Therapeutics' Phase...
areas including hematology, oncology, immunology, and rare diseases as well as novel technology platforms. Mr. Messerlian joined Creyon's Board of Directors as Executive Chairman and Acting CEO in early fall 2024. He brings extensive experience in...
help us quickly scale up our commercial efforts for a successful launch.” “This is an important and transformative time to join Neurotech as the company prepares for commercialization of the first and only approved treatment for adults suffering...
round led by Bender Analytical Holding B.V. (BAH). New investors Invest-NL, and the European Innovation Council (EIC) joined existing backers Oost NL and informal angels in the round. The funding accelerates the development of AMT’s ELANA® Heart...
(TDM), drugs of abuse screening, and other applications. "Bruker's majority investment in RECIPE and our planned joint introduction of high-throughput ClinDART® assays represents a significant advancement in clinical mass spectrometry," said Dr....
our founding, Truliant has delivered high-impact pharmacovigilance and risk management consulting to clients worldwide. Joining ELIQUENT Life Sciences marks an exciting new chapter - one where we will expand our pharmacovigilance expertise within a...
of the field of regenerative and cell therapy. This achievement is the result of a strategic collaboration(*2) and joint research between the two companies. The new production technology enables real-time monitoring of the quality of 3D cell...
18F or 68Ga for PET imaging, or with therapeutic isotopes such as 177Lu or 225Ac for radioligand therapy, all of which are joined together by a modifiable linker which can be used to modulate important pharmacokinetic characteristics. Radiohybrid...
Pharmaceuticals' extensive expertise in nasal and inhaled pharmaceutical development and manufacturing. The focus of this joint effort is to accelerate the preclinical development of novel therapies designed to enhance mucosal immunity in...
Psoriatic arthritis is a serious, highly heterogeneous, chronic, systemic inflammatory condition affecting both the joints and skin with a prevalence of 0.02 percent to 0.25 percent of the population.23 Psoriatic arthritis affects approximately 30...
Torsten Bove and Tomasz Zawada, founders of TOOsonix, expressed enthusiasm for the partnership: "We are thrilled to join forces with MikronMed to make our focused ultrasound therapy more easily accessible for patients across the Nordic region. Our...
uncovered $118 million in incremental revenue opportunities over a three-year forecast. Ashley shared her enthusiasm about joining the company, stating, “I am honored to join Vector Laboratories, a company with an unwavering commitment to...
